ASCO: New Agents Show Promise in HER2-Positive Breast Cancer

posted on Jun 08 by MedPage Today OB/Gyn in the Uncategorized category CHICAGO (MedPage Today) -- A small phase I clinical trial suggests that trastuzumab (Herceptin) conjugated to DM-1 (T-DM1) with or without pertuzumab has some effectiveness for women with advanced HER2-positive breast cancers previously treated with trastuzumab, researchers said here.